Lakefront Biotherapeutics wins FDA orphan drug status for gamgertamig in pemphigus

PUBT · 2d ago
Lakefront Biotherapeutics wins FDA orphan drug status for gamgertamig in pemphigus
  • FDA granted orphan drug designation to gamgertamig for pemphigus.
  • The drug already holds FDA fast track and orphan status in autoimmune hemolytic anemia, immune thrombocytopenia.
  • Program run with Gilead Sciences; Phase 1b autoimmune trials are enrolling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608241601PRIMZONEFULLFEED1001259131) on August 24, 2026, and is solely responsible for the information contained therein.